Purple Biotech Ltd. has entered into an agreement to acquire Immunorizon Ltd. for $3.5 million upfront, plus additional milestone payments, enhancing its portfolio of innovative oncology therapies.

Information on the Target

Immunorizon Ltd. is a private biopharmaceutical company specializing in oncology therapies. Their lead compound focuses on the 5T4 antigen, which plays a critical role in facilitating the conditional activation of T cells and natural killer (NK) cells. This innovative approach is designed to achieve a significant therapeutic index, enhancing the potential efficacy of treatments in targeting solid tumors.

With a portfolio that emphasizes multi-specific T and NK cell engager therapies, Immunorizon is at the forefront of addressing challenges such as tumor immune evasion and drug resistance. The company’s primary asset is a tri-specific antibody that presents a unique mechanism to selectively activate the immune response within the tumor's microenvironment, potentially offering a powerful addition to existing oncology treatment options.

Industry Overview in the Specific Country

The biotech industry, particularly in oncology, is experiencing substantial growth, driven by advances in immunotherapy and increasing investments in r